Clinical Trials Directory

Trials / Completed

CompletedNCT01555983

Vaporized Cannabis and Spinal Cord Injury Pain

The Effect of Vaporized Cannabis on Neuropathic Pain in Spinal Cord Injury

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
42 (actual)
Sponsor
Barth Wilsey · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

This study will demonstrate that vaporized marijuana results in antinociception when compared to placebo in subjects with spinal cord injury. To further evaluate potential benefits and side effects, the effect of different strengths of cannabis on mood, cognition, and psychomotor performance will also be measured.

Detailed description

This study will demonstrate that vaporized cannabis can produce antinociceptive effects compared to placebo in human subjects with spinal cord injury (SCI). A within-subject crossover study of the effects of cannabis versus placebo on spontaneous and evoked pain will be performed. A synopsis of antinociception with mood, cognitive impairment, psychomotor performance, and side effects will be obtained to help evaluate the utility of vaporized marijuana in SCI neuropathic pain. This study will compare the analgesic and side effect profile of low (3.5%) to high dose (7.0%) delta 9-tetrahydrocannabinol in subjects with spinal cord injury pain. It is hypothesized that a low dose will produce a lesser degree of neuropsychological impairment while maintaining a similar degree of pain relief to the higher dose. The use of two different strengths will help determine tolerable dosing for the treatment of SCI neuropathic pain.

Conditions

Interventions

TypeNameDescription
DRUGVaporization of CannabisRandomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC

Timeline

Start date
2012-07-01
Primary completion
2014-08-01
Completion
2014-08-01
First posted
2012-03-16
Last updated
2017-04-18
Results posted
2016-01-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01555983. Inclusion in this directory is not an endorsement.